Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1 , were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5′ untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1 . Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The high expression levels of ERG and PEA3 subfamily members in a subset of prostate tumors led to the discovery of common chromosomal rearrangements associated with this human cancer (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Chromosomal rearrangements that result in the overexpression of members of the PEA3 subfamily (ETV1, ETV4, or ETV5) are found less frequently (36, 170, 171).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
In the citing paper
“Rearrangements of ETS loci are a hallmark of prostate cancer with ~50% of tumors showing alterations at an ETS gene locus (36).”
From Genomic and biochemical insights into the specificity of ETS transcription factors (2011) · cites this paper as [36]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Self-citationA census of human cancer genes
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., Rahman, N., & Stratton, M. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1299 · Cited by 3,184
Sotiriou, C., Neo, S.-Y., McShane, L. M., Korn, E. L., Long, P. M., Jazaeri, A., Martiat, P., Fox, S. B., Harris, A. L., & Liu, E. T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1732912100 · Cited by 1,993
Delineation of prognostic biomarkers in prostate cancer
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M. (2001) · Nature · doi:10.1038/35090585 · Cited by 1,673
Self-citationChromosomal translocations in human cancer
Rabbitts, T. H. (1994) · Nature · doi:10.1038/372143a0 · Cited by 1,503
Tian, E., Zhan, F., Walker, R., Rasmussen, E., Ma, Y., Barlogie, B., & Shaughnessy, J. D. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030847 · Cited by 1,503
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R. (1982) · Nature · doi:10.1038/300765a0 · Cited by 1,378
Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia
Valk, P. J. M., Verhaak, R. G. W., Beijen, M. A., Erpelinck, C. A. J., van Doorn-Khosrovani, S. B. V. W., Boer, J. M., Beverloo, H. B., Moorhouse, M. J., van der Spek, P. J., Löwenberg, B., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040465 · Cited by 1,370
Research works printed but not linked: 5
- I. S. Jeon et al., Oncogene10, 1229 (1995).
- B. Lin et al., Cancer Res.59, 4180 (1999).
- D. E. Afar et al., Cancer Res.61, 1686 (2001).
- S. M. Dhanasekaran et al., FASEB J.19, 243 (2005).
- J. B. Welsh et al., Cancer Res.61, 5974 (2001).
Cited by
Items 501–600 of 1,014
RETRACTED: EPCA-2: A Highly Specific Serum Marker for Prostate Cancer
Leman, E. S., Cannon, G. W., Trock, B. J., Sokoll, L. J., Chan, D. W., Mangold, L. A., Partin, A. W., & Getzenberg, R. H. (2007) · Urology · doi:10.1016/j.urology.2007.01.097 · Cited by 125
RetractedGenomic and proteomic biomarkers for cancer: A multitude of opportunities
Tainsky, M. A. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.04.004 · Cited by 153
Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and TherapiesPreprint
Puca, L., Vlachostergios, P. J., & Beltran, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030593 · Cited by 126
“As opposed to TMPRSS2ERG fusion-positive prostate adenocarcinomas in which ERG protein is overexpressed (Tomlins et al. 2005; Park et al. 2014), ERG may not be overexpressed in TMPRSS2-ERG-positive CRPCNE tumors as ERG protein expression is driven by its androgen-driven partner TMPRSS2, and 4…”
BackgroundScarfò, I., Pellegrino, E., Mereu, E., Kwee, I., Agnelli, L., Bergaggio, E., Garaffo, G., Vitale, N., Caputo, M., Machiorlatti, R., et al. (2016) · Blood · doi:10.1182/blood-2014-12-614503 · Cited by 115
Emerging biomarkers in the diagnosis of prostate cancer
Filella, X., Fernández‐Galán, E., Fernández, R. M. S., & Foj, L. (2018) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s136026 · Cited by 143
Zhuang, J., Widschwendter, M., & Teschendorff, A. E. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-59 · Cited by 119
Evaluating Localized Prostate Cancer and Identifying Candidates for Focal Therapy
Sartor, O. A., Hricak, H., Wheeler, T. M., Coleman, J., Penson, D. F., Carroll, P. R., Rubin, M. A., & Scardino, P. T. (2008) · Urology · doi:10.1016/j.urology.2008.10.004 · Cited by 124
Self-citationClinical use of novel urine and blood based prostate cancer biomarkers: A review
Dijkstra, S., Mulders, P., & Schalken, J. A. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.10.023 · Cited by 134
Hoogland, A. M., Jenster, G. W., van Weerden, W. M., Trapman, J., van der Kwast, T., Roobol, M. J., Schröder, F. H., Wildhagen, M. F., & van Leenders, G. J. L. H. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.176 · Cited by 129
“2 is the most common genetic alteration in prostate cancer occurring in 40–70p of tumors”
BackgroundStankiewicz, M. J., & Crispino, J. D. (2009) · Blood · doi:10.1182/blood-2008-08-174813 · Cited by 132
Novel Biomarkers for Prostate Cancer Including Noncoding Transcripts
Romanuik, T. L., Ueda, T., Le, N., Haile, S., Yong, T. M. K., Thomson, T. A., Vessella, R. L., & Sadar, M. D. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080868 · Cited by 122
Gene regulatory mechanisms underpinning prostate cancer susceptibility
Whitington, T., Gao, P. H., Song, W., Ross‐Adams, H., Lamb, A. D. G., Yang, Y., Svezia, I., Klevebring, D., Mills, I. G., Karlsson, R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3523 · Cited by 132
Binding of TMPRSS2-ERG to BAF Chromatin Remodeling Complexes Mediates Prostate Oncogenesis
Sandoval, G. J., Pulice, J. L., Pakula, H., Schenone, M., Takeda, D. Y., Pop, M., Boulay, G., Williamson, K. E., McBride, M. J., Pan, J., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.06.040 · Cited by 121
“Identification of Endogenous TMPRSS2-ERG Protein Interactions To understand the mechanisms by which ERG drives oncogenic gene expression programs, we first sought to identify ERG interacting proteins in prostate cancer cells that contain the TMPRSS2-ERG fusion and hence high levels of ERG mRNA and protein (VCaP cell l…”
ETV1 Is a Novel Androgen Receptor-Regulated Gene that Mediates Prostate Cancer Cell Invasion
Cai, C., Hsieh, C.-L., Omwancha, J., Zheng, Z., Chen, S.-Y., Baert, J.-L., & Shemshedini, L. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0480 · Cited by 120
Translational genomics: The challenge of developing cancer biomarkers
Brooks, J. D. (2012) · Genome Research · doi:10.1101/gr.124347.111 · Cited by 119
Transcriptome-guided characterization of genomic rearrangements in a breast cancer cell line
Zhao, Q., Caballero, O. L., Levy, S., Stevenson, B. J., Iseli, C., de Souza, S. J., Galante, P. A., Busam, D., Leversha, M. A., Chadalavada, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812945106 · Cited by 123
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation
Rasool, R. U., Natesan, R., Deng, Q., Aras, S., Lal, P., Effron, S. S., Mitchell-Velasquez, E., Posimo, J. M., Carskadon, S. L., Baca, S. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0189 · Cited by 133
Neuroendocrine Differentiation of Prostate Cancer—An Intriguing Example of Tumor Evolution at Play
Patel, G. K., Chugh, N., & Tripathi, M. (2019) · Cancers · doi:10.3390/cancers11101405 · Cited by 127
Shao, J., Yan, Y., Ding, D., Wang, D., He, Y., Pan, Y., Yan, W., Kharbanda, A., Li, H., & Huang, H. (2021) · Advanced Science · doi:10.1002/advs.202102555 · Cited by 117
Jeong, M., Ocwieja, K. E., Han, D., Wackym, P. A., Zhang, Y., Brown, A., Moncada-Reid, C., Vambutas, A., Kanne, T. J., Crain, R., et al. (2021) · Communications Medicine · doi:10.1038/s43856-021-00044-w · Cited by 126
Patel, M., Simon, J. M., Iglesia, M. D., Wu, S. B., McFadden, A. W., Lieb, J. D., & Davis, I. J. (2012) · Genome Research · doi:10.1101/gr.125666.111 · Cited by 114
PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer
Bismar, T. A., Yoshimoto, M., Vollmer, R. T., Duan, Q., Firszt, M., Corcos, J., & Squire, J. A. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09470.x · Cited by 130
Song, H., Zhang, B., Watson, M. A., Humphrey, P. A., Lim, H. J., & Milbrandt, J. (2009) · Oncogene · doi:10.1038/onc.2009.181 · Cited by 123
Wang, Q., Xia, J., Jia, P., Pao, W. J., & Zhao, Z. (2012) · Briefings in Bioinformatics · doi:10.1093/bib/bbs044 · Cited by 127
Kalna, V., Yang, Y., Peghaire, C. R., Frudd, K., Hannah, R., Shah, A. V., Osuna Almagro, L., Boyle, J. J., Göttgens, B., Ferrer, J., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.313788 · Cited by 119
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
Majewski, I. J., Mittempergher, L., Davidson, N., Bosma, A. R., Willems, S. M., Horlings, H. M., de Rink, I., Greger, L., Hooijer, G. K. J., Peters, D. D. G. C., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4209 · Cited by 132
Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours
Parker, B. C., Engels, M., Annala, M., & Zhang, W. (2013) · The Journal of Pathology · doi:10.1002/path.4297 · Cited by 130
Matsuyama, A., Hisaoka, M., Nagao, Y., & Hashimoto, H. (2011) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-011-1063-4 · Cited by 119
“Recent cytogenetic and molecular tumor analyses identified several tumor-specific chromosomal alterations and their molecular consequences in many types of malignancies including not only hematopoietic or mesenchymal neoplasms but also epithelial tumors such as pulmonary adenocarcinoma [21], prostatic adenocarcinoma […”
BackgroundIntegrative Analysis of Genomic Aberrations Associated with Prostate Cancer Progression
Kim, J. H., Dhanasekaran, S. M., Mehra, R., Tomlins, S. A., Gu, W., Yu, J., Kumar-Sinha, C., Cao, X., Dash, A., Wang, L., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1297 · Cited by 122
Self-citationAKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis
Li, N., Xue, W., Yuan, H., Dong, B., Ding, Y., Liu, Y., Jiang, M., Kan, S., Sun, T., Ren, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91144 · Cited by 120
Molecular Subtypes of Prostate Cancer
Arora, K., & Barbieri, C. E. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0707-9 · Cited by 133
In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells
Martinez-Lage, M., Torres-Ruiz, R., Puig-Serra, P., Moreno-Gaona, P., Martin, M. C., Moya, F. J., Quintana-Bustamante, O., Garcia-Silva, S., Carcaboso, A. M., Petazzi, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18875-x · Cited by 115
Baratchian, M., McManus, J. M., Berk, M. P., Nakamura, F., Mukhopadhyay, S., Xu, W., ERZURUM, S. C., Drazba, J. A., Peterson, J. W., Klein, E. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-90491-1 · Cited by 122
The hallmarks of castration-resistant prostate cancers
Katsogiannou, M., Ziouziou, H., Karaki, S., Andrieu, C., de Villeneuve, M. H., & Rocchi, P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.003 · Cited by 123
Tindall, D. J., & Rittmaster, R. S. (2008) · The Journal of Urology · doi:10.1016/j.juro.2007.11.033 · Cited by 142
Li, J., Lai, Y., Ma, J., Liu, Y., Bi, J., Zhang, L., Chen, L., Chen, Y., Lv, W., Chang, G., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3674-x · Cited by 118
The Ets transcription factors of the PEA3 group: Transcriptional regulators in metastasis
de Launoit, Y., Baert, J., Chotteau‐Lelièvre, A., Monté, D., Coutte, L., Mauën, S., Firlej, V., Degerny, C., & Verreman, K. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.02.002 · Cited by 129
Teschendorff, A. E., & Widschwendter, M. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts170 · Cited by 119
“A CpG constitutes a methylation outlier (or ‘hit’) in that sample if the CpG exhibits abnormally high methylation compared with the median value across all samples as determined by the COPA transformation (Tomlins et al., 2005) and a threshold parameter (Section 2).”
MethodInfluentialAndrogen regulation of gene expression.
(2010) · Advances in cancer research · doi:10.1016/s0065-230x(10)07005-3 · Cited by 117
Giacomini, C. P., Sun, S., Varma, S., Shain, A. H., Giacomini, M. M., Balagtas, J. M. S., Sweeney, R. T., Lai, E., Fitz, C. D. V., Forster, A. D., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003464 · Cited by 123
Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer
El-Kenawi, A., Dominguez-Viqueira, W., Liu, M., Awasthi, S., Abraham-Miranda, J., Keske, A., Steiner, K. K., Noel, L., Serna, A. N., Dhillon, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-4028 · Cited by 113
Mouse models of prostate cancer: picking the best model for the question
Grabowska, M. M., DeGraff, D. J., Yu, X., Jin, R. J., Chen, Z., Borowsky, A. D., & Matusik, R. J. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9487-8 · Cited by 132
Kruse, E. A., Loughran, S. J., Baldwin, T. M., Josefsson, E. C., Ellis, S., Watson, D. K., Nurden, P., Metcalf, D., Hilton, D. J., Alexander, W. S., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906556106 · Cited by 110
Steroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
Molecular pathways and targets in prostate cancer
Shtivelman, E., Beer, T. M., & Evans, C. P. (2014) · Oncotarget · doi:10.18632/oncotarget.2406 · Cited by 127
TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate☆
Guo, C. C., Dancer, J. Y., Wang, Y., Aparicio, A., Navone, N. M., Troncoso, P., & Czerniak, B. A. (2011) · Human Pathology · doi:10.1016/j.humpath.2010.05.026 · Cited by 114
Epigenetics of prostate cancer: beyond DNA methylation
Schulz, W. A., & Hatina, J. (2006) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2006.tb00293.x · Cited by 116
Yan, J., Erdem, H., Li, R., Cai, Y., Ayala, G., Ittmann, M., Yu‐Lee, L., Tsai, S. Y., & Tsai, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0955 · Cited by 117
An Oncogenic Role for ETV1 in Melanoma
Jané-Valbuena, J., Widlund, H. R., Perner, S., Johnson, L. A., Dibner, A. C., Lin, W. M., Baker, A. C., Nazarian, R. M., Vijayendran, K. G., Sellers, W. R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3092 · Cited by 115
Self-citationGamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancer
Kawakami, K., Fujita, Y., Matsuda, Y., Arai, T., Horie, K., Kameyama, K., Kato, T., Masunaga, K., Kasuya, Y., Tanaka, M., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3301-x · Cited by 118
Massoner, P., Thomm, T., Mack, B., Untergasser, G., Martowicz, A., Bobowski, K. D., Klocker, H., Gires, O., & Puhr, M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.366 · Cited by 115
Asmann, Y. W., Hossain, A., Necela, B. M., Middha, S., Kalari, K. R., Sun, Z., Chai, H. S., Williamson, D. W., Radisky, D. C., Schroth, G. P., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr362 · Cited by 152
CYP17 inhibition as a hormonal strategy for prostate cancer
Reid, A. H. M., Attard, G., Barrie, E., & Bono, J. S. D. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1237 · Cited by 119
“The biological significance of these androgen-driven translocations, however, is not yet fully understood”
BackgroundETS rearrangements and prostate cancer initiation
Carver, B. S., Tran, J., Chen, Z., Carracedo-Perez, A., Alimonti, A., Nardella, C., Gopalan, A., Scardino, P. T., Cordon-Cardo, C., Gerald, W., et al. (2009) · Nature · doi:10.1038/nature07738 · Cited by 111
van Leenders, G. J. L. H., Boormans, J. L., Vissers, C. J., Hoogland, A. M., Bressers, A. A., Furusato, B., & Trapman, J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.65 · Cited by 124
COPA—cancer outlier profile analysis
MacDonald, J. W., & Ghosh, D. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl433 · Cited by 124
Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
Kahn, B., Collazo, J., & Kyprianou, N. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.8671 · Cited by 122
YK-4-279 Inhibits ERG and ETV1 Mediated Prostate Cancer Cell Invasion
Rahim, S., Beauchamp, E. M., Kong, Y., Brown, M. L., Toretsky, J. A., & Üren, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019343 · Cited by 117
Mechanisms of Non-Opioid Analgesics Beyond Cyclooxygenase Enzyme Inhibition
Hamza, M., & Dionne, R. (2009) · Current Molecular Pharmacology · doi:10.2174/1874467210902010001 · Cited by 108
Cancer whole-genome sequencing: present and future
Nakagawa, H., Wardell, C. P., Furuta, M., Taniguchi, H., & Fujimoto, A. (2015) · Oncogene · doi:10.1038/onc.2015.90 · Cited by 123
Discovery of CTCF-Sensitive Cis-Spliced Fusion RNAs between Adjacent Genes in Human Prostate Cells
Qin, F., Song, Z., Babiceanu, M., Song, Y., Facemire, L., Singh, R., Adli, M., & Li, H. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005001 · Cited by 120
Kiaii, S., Clear, A. J., Ramsay, A. G., Davies, D., Sangaralingam, A., Lee, A., Calaminici, M., Neuberg, D. S., & Gribben, J. G. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2137 · Cited by 104
DNA damage response and prostate cancer: defects, regulation and therapeutic implications
Karanika, S., Karantanos, T., Li, L., Corn, P. G., & Thompson, T. C. (2014) · Oncogene · doi:10.1038/onc.2014.238 · Cited by 117
Advancing a clinically relevant perspective of the clonal nature of cancer
Ruiz, C. F., Lenkiewicz, E., Evers, L., Holley, T., Robeson, A., Kiefer, J., Demeure, M. J., Hollingsworth, M. A., Shen, M., Prunkard, D. E., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104009108 · Cited by 121
Prostate Cancer Biomarker Profiles in Urinary Sediments and Exosomes
Dijkstra, S., Birker, I. L., Smit, F. P., Leyten, G. H. J. M., de Reijke, T. M., van Oort, I. M., Mulders, P., Jannink, S. A., & Schalken, J. A. (2013) · The Journal of Urology · doi:10.1016/j.juro.2013.11.001 · Cited by 111
Neuroendocrine tumors of the prostate
Fine, S. W. (2018) · Modern Pathology · doi:10.1038/modpathol.2017.164 · Cited by 123
Du, Q., Bert, S. A., Armstrong, N. J., Caldon, C. E., Song, J. Z., Nair, S. S., Gould, C. M., Luu, P., Peters, T. J., Khoury, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08302-1 · Cited by 114
PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription
Kanteti, R., Nallasura, V., Loganathan, S., Tretiakova, M., Kroll, T. G., Krishnaswamy, S., Faoro, L. N., Cagle, P. T., Husain, A. N., Vokes, E. E., et al. (2009) · Laboratory Investigation · doi:10.1038/labinvest.2008.168 · Cited by 111
Golgi Protein GOLM1 Is a Tissue and Urine Biomarker of Prostate Cancer
Varambally, S., Laxman, B., Mehra, R., Cao, Q., Dhanasekaran, S. M., Tomlins, S. A., Granger, J. I., Vellaichamy, A., Sreekumar, A., Yu, J., et al. (2008) · Neoplasia · doi:10.1593/neo.08922 · Cited by 111
Self-citationMerging new-age biomarkers and nanodiagnostics for precision prostate cancer management
Koo, K. M., Mainwaring, P. N., Tomlins, S. A., & Trau, M. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0178-2 · Cited by 115
Self-citationHeterogeneity and clinical significance of ETV1 translocations in human prostate cancer
on behalf of the Transatlantic Prostate Group, Attard, G., Clark, J., Ambroisine, L., Mills, I. G., Fisher, G., Flohr, P., Reid, A. H. M., Edwards, S. E., Kovács, G., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604472 · Cited by 117
Intergenically Spliced Chimeric RNAs in Cancer
Jia, Y., Xie, Z., & Li, H. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.07.006 · Cited by 115
Sex‐related differences in COVID‐19 lethality
Penna, C. R. R., Mercurio, V., Tocchetti, C. G., & Pagliaro, P. (2020) · British Journal of Pharmacology · doi:10.1111/bph.15207 · Cited by 121
Targeting Androgen Regulation of TMPRSS2 and ACE2 as a Therapeutic Strategy to Combat COVID-19
Deng, Q., Rasool, R. U., Russell, R. M., Natesan, R., & Asangani, I. A. (2020) · iScience · doi:10.1016/j.isci.2021.102254 · Cited by 112
“More than half of all prostate cancers in men of European ancestry harbor a gene fusion that juxtaposes the androgen receptor (AR) regulatory promoter/enhancer elements of Tmprss2 in front of the ETS family transcription factors, most commonly Erg(Tomlins et al., 2005).”
BackgroundIanculescu, I., Wu, D., Siegmund, K. D., & Stallcup, M. R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.300194 · Cited by 116
Identification of novel androgen receptor target genes in prostate cancer
Jariwala, U., Prescott, J., Li, J., Barski, A., Pregizer, S., Cogan, J. P., Arasheben, A., Tilley, W. D., Scher, H. I., Gerald, W. L., et al. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-39 · Cited by 119
Antonarakis, E. S., Keizman, D., Zhang, Z., Gurel, B., Lotan, T. L., Hicks, J. L., Fedor, H. L., Carducci, M. A., De Marzo, A. M., & Eisenberger, M. A. (2012) · Cancer · doi:10.1002/cncr.27689 · Cited by 107
Xi, L., Feber, A., Gupta, V., Wu, M., Bergemann, A. D., Landreneau, R. J., Litle, V. R., Pennathur, A., Luketich, J. D., & Godfrey, T. E. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn697 · Cited by 107
Prostate cancer incidence in males with Lynch syndrome
Haraldsdóttir, S., Hampel, H., Wei, L., Wu, C. S.-Y., Frankel, W. L., Bekaii‐Saab, T., de la Chapelle, A., & Goldberg, R. M. (2014) · Genetics in Medicine · doi:10.1038/gim.2013.193 · Cited by 125
Utilizing circulating tumor cells: challenges and pitfalls
Attard, G., & Bono, J. S. D. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2010.10.010 · Cited by 115
“As ERG gene rearrangements were previously reported as only present in neoplastic and preneoplastic tissue and never in normal cells [20,21] this observation could suggest that CTC detected using CellSearch are malignant in origin.”
ResultSmith, I. M., Glazer, C. A., Mithani, S. K., Ochs, M. F., Sun, W., Bhan, S., Vostrov, A. A., Abdullaev, Z., Lobanenkov, V. V., Gray, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004961 · Cited by 113
Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer
Hartmaier, R. J., Trabucco, S. E., Priedigkeit, N., Chung, J., Parachoniak, C. A., Borre, P. V., Morley, S., Rosenzweig, M. R., Gay, L. M., Goldberg, M. E., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy025 · Cited by 109
Extracellular vesicles in urological malignancies: an update
Linxweiler, J., & Junker, K. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0261-8 · Cited by 117
Androgen signaling and its interactions with other signaling pathways in prostate cancer
Kaarbø, M., Klokk, T. I., & Saatcioglu, F. (2007) · BioEssays · doi:10.1002/bies.20676 · Cited by 126
Ketola, K., Vainio, P., Fey, V., Kallioniemi, O., & Iljin, K. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0368 · Cited by 116
Haffner, M. C., Marzo, A. M. D., Meeker, A. K., Nelson, W. G., & Yegnasubramanian, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2044 · Cited by 119
Exosomal Secretion of Cytoplasmic Prostate Cancer Xenograft-derived Proteins
Jansen, F. H., Krijgsveld, J., van Rijswijk, A., van den Bemd, G.-J., van den Berg, M. S., van Weerden, W. M., Willemsen, R., Dekker, L. J., Luider, T. M., & Jenster, G. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800443-mcp200 · Cited by 107
O'Sullivan, C. C., Moon, D. H., Kohn, E. C., & Lee, J. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00042 · Cited by 119
Two Unique Novel Prostate-Specific and Androgen-Regulated Fusion Partners of ETV4 in Prostate Cancer
Hermans, K. G., Bressers, A. A., van der Korput, H. A., Dits, N. F. J., Jenster, G. W., & Trapman, J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0198 · Cited by 124
The Role of Genetic Markers in the Management of Prostate Cancer
Choudhury, A. D., Eeles, R. A., Freedland, S. J., Isaacs, W. B., Pomerantz, M. M., Schalken, J. A., Tammela, T. L. J., & Visakorpi, T. (2012) · European Urology · doi:10.1016/j.eururo.2012.05.054 · Cited by 116
An algorithm for assembly of ordered restriction maps from single DNA molecules
Valouev, A., Schwartz, D. C., Zhou, S., & Waterman, M. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604040103 · Cited by 118
Park, K., Dalton, J. T., Narayanan, R., Barbieri, C. E., Hancock, M. L., Bostwick, D. G., Steiner, M. S., & Rubin, M. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8386 · Cited by 112
Self-citationHistone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1
Kim, T., Jin, F., Shin, S., Oh, S., Lightfoot, S. A., Grande, J. P., Johnson, A. J., van Deursen, J. M., Wren, J. D., & Janknecht, R. (2016) · Journal of Clinical Investigation · doi:10.1172/jci78132 · Cited by 110
The diverse roles of SPOP in prostate cancer and kidney cancer
Wang, Z. P., Song, Y., Ye, M., Dai, X., Zhu, X., & Wei, W. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-0314-z · Cited by 115
A novel KIF5B‐ALK variant in nonsmall cell lung cancer
Wong, D. W., Leung, E. L., Wong, S. K., Tin, V. P., Sihoe, A. D., Cheng, L., Au, J. S. K., Chung, L., & Wong, M. P. (2011) · Cancer · doi:10.1002/cncr.25843 · Cited by 107
Type II transmembrane serine proteases in cancer and viral infections
Choi, S.-Y., Bertram, S., Glowacka, I., Park, Y. W., & Pöhlmann, S. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.05.003 · Cited by 112
Unraveling the clonal hierarchy of somatic genomic aberrations
Prandi, D., Baca, S. C., Romanel, A., Barbieri, C. E., Mosquera, J., Fontugne, J., Beltran, H., Sboner, A., Garraway, L. A., Rubin, M. A., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0439-6 · Cited by 108
Self-citationLeinonen, K. A., Tolonen, T. T., Bracken, H., Stenman, U., Tammela, T. L. J., Saramäki, O. R., & Visakorpi, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2505 · Cited by 104
Androgen receptor genomic regulation.
Jin, H., Kim, J., & Yu, J. (2013) · PubMed Central · doi:10.3978/j.issn.2223-4683.2013.09.01 · Cited by 139
Understanding the Role of ETS-Mediated Gene Regulation in Complex Biological Processes
Findlay, V. J., LaRue, A. C., Turner, D. P., Watson, P. M., & Watson, D. K. (2013) · Advances in cancer research · doi:10.1016/b978-0-12-407190-2.00001-0 · Cited by 125
Metadata
- Authors
- Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., Lee, C., Montie, J. E., Shah, R. B., Pienta, K. J., Rubin, M. A., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Department of Pathology, University of Michigan Medical School, 1301 Catherine Street, Ann Arbor, MI 48109–0602, USA.
- Corresponding author
- Chinnaiyan, Arul M.
- ORCID
- Venue
- Science
- Published
- 2005-10-28
- Volume
- 310
- Issue
- 5748
- Pages
- 644-648
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2121158863
- Cited by
- 3,846
- References
- 32
- Citations by year
- 2026: 77 · 2025: 99 · 2024: 82 · 2023: 108 · 2022: 137 · 2021: 163 · 2020: 187 · 2019: 172 · 2018: 178 · 2017: 218 · 2016: 209 · 2015: 244 · 2014: 271 · 2013: 309 · 2012: 279
- FWCI
- 114.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (R01AG021404, R01 AG 21404)
- National Cancer Institute (UO1 CA111275-01, P50-CA-69568, U01CA111275, R01CA097063, R01 CA97063, 5P30 CA 46592, P50CA069568, P30CA046592)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- TMPRSS2-ERG fusion, prostate cancer, ETS transcription factors, chromosomal rearrangements, gene fusion, molecular diagnosis
- MeSH terms
- Transcriptional Regulator ERG, Androgens, DNA-Binding Proteins, Humans, Male, Membrane Proteins, Molecular Sequence Data, Neoplasm Proteins, Prostatic Neoplasms, Serine Endopeptidases, Transcription Factors, Translocation, Genetic, Gene Rearrangement, Oncogene Proteins, Fusion, Trans-Activators, Gene Expression Regulation, Neoplastic, Polymerase Chain Reaction, In Situ Hybridization, Fluorescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.